{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:58Z","timestamp":1784347438062,"version":"3.55.0"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.2169\/internalmedicine.6559-25","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T22:06:56Z","timestamp":1764799616000},"page":"1943-1947","source":"Crossref","is-referenced-by-count":0,"title":["Little Evidence of Atherosclerosis in a Middle-aged Japanese Woman with Familial Hypercholesterolemia Carrying &lt;i&gt;PCSK9&lt;\/i&gt; (p.Glu32Lys) and &lt;i&gt;ABCG8&lt;\/i&gt; (p.Ile419Asn) Variants despite Elevated Lipoprotein (a) Levels"],"prefix":"10.2169","volume":"65","author":[{"given":"Kazuto","family":"Aono","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Maezawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[{"name":"Chiba University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Nordestgaard BG, Chapman MJ, Humphries SE, et al.; the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34: 3478-3490a, 2013."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jacobson TA, Maki KC, Orringer CE, et al.; the NLA Expert Panel. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol 9 (6 Suppl): S1-S122.e1, 2015.","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Hori M, Ohta N, Takahashi A, et al. Impact of <i>LDLR<\/i> and <i>PCSK9<\/i> pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. Atherosclerosis 289: 101-108, 2019.","DOI":"10.1016\/j.atherosclerosis.2019.08.004"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Mabuchi H, Nohara A, Noguchi T, et al.; The Hokuriku FH Study Group. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/ kexin type 9 (<i>PCSK9<\/i>) gain-of-function mutation. Atherosclerosis 236: 54-61, 2014.","DOI":"10.1016\/j.atherosclerosis.2014.06.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol 12: 1436-1444, 2018.","DOI":"10.1016\/j.jacl.2018.08.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kamstrup PR, Tybj\u00e6rg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 301: 2331-2339, 2009.","DOI":"10.1001\/jama.2009.801"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Langsted A, Kamstrup PR, Benn M. Tybj\u00e6rg-Hansen A, Nordestgaard BG. High lipoprotein (a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol 4: 577-587, 2016.","DOI":"10.1016\/S2213-8587(16)30042-0"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Noguchi T, Katsuda S, Kawashiri MA, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210: 166-172, 2010.","DOI":"10.1016\/j.atherosclerosis.2009.11.018"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by <i>PCSK9<\/i> gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet 8: 823-831, 2015.","DOI":"10.1161\/CIRCGENETICS.115.001129"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tajima T, Morita H, Ito K, et al. Blood lipid-related low-frequency variants in <i>LDLR<\/i> and <i>PCSK9<\/i> are associated with onset age and risk of myocardial infarction in Japanese. Sci Rep 8: 8107, 2018.","DOI":"10.1038\/s41598-018-26453-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Doi T, Hori M, Harada-Shiba M, et al. Patients with <i>LDLR<\/i> and <i>PCSK9<\/i> gene variants experienced higher incidence of cardiovascular outcomes in heterozygous familial hypercholesterolemia. J Am Heart Assoc 10: e018263, 2021.","DOI":"10.1161\/JAHA.120.018263"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tada H, Okada H, Nomura A, et al. Rare and deleterious mutations in ABCG5\/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J 83: 1917-1924, 2019.","DOI":"10.1253\/circj.CJ-19-0317"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Reeskamp LF, Volta A, Zuurbier L, Defesche JC, Hovingh GK, Grefhorst A. <i>ABCG5<\/i> and <i>ABCG8<\/i> genetic variants in familial hypercholesterolemia. J Clin Lipidol 14: 207-217.e7, 2020.","DOI":"10.1016\/j.jacl.2020.01.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nomura A, Emdin CA, Won HH, et al. Heterozygous <i>ABCG5<\/i> gene deficiency and risk of coronary artery disease. Circ Genomic Precis Med 13: 417-423, 2020.","DOI":"10.1161\/CIRCGEN.119.002871"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tada H, Okada H, Nomura A, Takamura M, Kawashiri M. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis 19: 3, 2020.","DOI":"10.1186\/s12944-019-1183-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Clarke R, Peden JF, Hopewell JC, et al.; the PROCARDIS Consortium. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-2528, 2009.","DOI":"10.1056\/NEJMoa0902604"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 43: 3925-3946, 2022.","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tada H, Kawashiri MA, Yoshida T, et al. Lipoprotein (a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (<i>PCSK9<\/i>) gain-of-function mutations. Circ J 80: 512-518, 2016.","DOI":"10.1253\/circj.CJ-15-0999"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 1: 767-776, 2016.","DOI":"10.1001\/jamacardio.2016.2415"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Akioyamen LE, Genest J, Chu A, Inibhunu H, Ko DT, Tu JV. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. J Clin Lipidol 13: 15-30, 2019.","DOI":"10.1016\/j.jacl.2018.10.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fahed AC, Wang M, Patel AP, et al. Association of the interaction between familial hypercholesterolemia variants and adherence to a healthy lifestyle with risk of coronary artery disease. JAMA Netw Open 5: e222687, 2022.","DOI":"10.1001\/jamanetworkopen.2022.2687"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371: 2383-2393, 2014.","DOI":"10.1056\/NEJMoa1409065"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tada H, Okada H, Nohara A, et al. Impact of high-density lipoprotein function, rather than high-density lipoprotein cholesterol level, on cardiovascular disease among patients with familial hypercholesterolemia. Circ J 87: 806-812, 2023.","DOI":"10.1253\/circj.CJ-22-0560"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ogura M, Hori M, Harada-Shiba M. Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 36: 181-188, 2016.","DOI":"10.1161\/ATVBAHA.115.306665"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_6559-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:26:22Z","timestamp":1784345182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_6559-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":24,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6559-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"6559-25"}}